Oruka Therapeutics to report Week 16 ORKA-001 EVERLAST-A Phase 2a data April 27

Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

0.00
  • Oruka Therapeutics scheduled release of Week 16 data for ORKA-001 from ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis for April 27, 2026.
  • Results have not yet been presented.
  • Conference call and webcast set for 8:00 a.m. ET to discuss trial readout.
  • Update could clarify ORKA-001’s emerging clinical profile in chronic skin disease, a key driver for pipeline valuation and next-stage development plans.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604261200PRIMZONEFULLFEED9706990) on April 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.